Skip to main content

Additional Advances in Immune Thrombocytopenia Research and Clinical Trials With Allison Imahiyerobo, APN

In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyerobo sat down with Oncology Data Advisor to discuss additional advancements and updates in ITP management and patient care since recording. Oncology Dat...

Continue reading

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.  

Continue reading

Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP

Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected.

In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Continue reading

Addressing Knowledge Gaps in the Treatment of Metastatic Colorectal Cancer

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...

Continue reading

Confronting Educational Needs in Treatment of Myelofibrosis

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for the management and treatment of patients with myelofibrosis. Myelofibrosis, considered a form of chronic leukemia, is a rare type of myeloproliferative neoplasm. An estimated one-third of individuals who have myelofibrosis will not show any symptoms in the early stages of the disorder, which can last many years. However, as the disease develops, they will begin to exhibit symptoms s...

Continue reading

Expertise and Knowledge Gains Made for Treatment of Prostate Cancer

An educational live and enduring activity provided by i3 Health has demonstrated increased expertise and learning outcomes for treatment of patients with prostate cancer. Prostate cancer is the most common cancer in American men, seeing an average of 1 out of 8 men being diagnosed with it within their lifetime. The typical treatment for progressive prostate disease is androgen deprivation therapy (ADT); however, it is common for prostate cancer to become castration-resistant or resistant to ADT....

Continue reading

Supporting Educational Needs in Treatment of Advanced Non–Small Cell Lung Cancer

An educational enduring activity provided by i3 Health demonstrated significant learning outcomes in the selection of treatment for patients with anaplastic lymphoma kinase (ALK)–positive advanced non–small cell lung cancer (NSCLC). This activity was created to advise clinicians on the development of individualized treatment plans based on the best available evidence and emerging guideline recommendations. Lung cancer is the second most common cancer in the United States, and the first most dead...

Continue reading

Educational Needs in the Management of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Continue reading

Educational Needs in Hematopoietic Stem Cell Transplant: Eligibility Criteria, Transplant Benefits, and Risks

When patients with hematological malignancies do not receive referrals for hematopoietic stem cell transplant (HSCT), they may face a risk of poorer outcomes. Common reasons behind this lack of referrals include provider confusion over eligibility criteria for HSCT, overestimation of the risks associated with transplant, and confusion regarding the benefit of HSCT. This educational gap regarding the uses and risks of HSCT was identified in the baseline data collected from i3 Health's continuing ...

Continue reading

Addressing Gaps in Knowledge of Best Practices in Metastatic Triple-Negative Breast Cancer

Of all women diagnosed with cancer in the United States, 30% have breast cancer, which is the second-leading cause of cancer death in this group. Many women have benefitted from regular screening as well as earlier and improved treatment; however, 6% of women present with metastatic disease, and 30% with no initial lymph node involvement will develop metastatic disease. Women with metastatic breast cancer have a poorer prognosis than the overall population of breast cancer patients, and research...

Continue reading

Learning Needs in Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...

Continue reading

Knowledge Gaps Revealed in Waldenström Macroglobulinemia

Waldenström macroglobulinemia is a rare lymphoproliferative disorder, with an estimated 1,500 new cases reported in the United States each year. This malignancy, which accounts for 2% of non-Hodgkin lymphomas, is characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM). It is important for health care professionals involved in the care of patients with Waldenström macroglobulinemia to remain up to date in their knowledge of risk stra...

Continue reading

Metastatic Gastric Cancer: Educational Needs

Due to the advances in treatment options for metastatic gastric cancer in recent years, oncology physicians and nurses can individualize treatment selection for patients by considering pathologic and molecular characteristics and emerging efficacy and safety data on novel therapies. Baseline data collected from i3 Health's continuing medical education (CME)/nursing continuing professional development (NCPD)–approved visiting faculty meeting series titled Challenges and Opportunities in Metastati...

Continue reading

Knowledge Gaps Identified in Treating Recurrent Ovarian Cancer With PARP Inhibitors

As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such as patient health status, predictive/prognostic markers, disease-free interval, number of lines and agents used previously, toxicities remaining from previous lines of therapy, and the extent of disease relapse. The new research constantly being conducted creates anoth...

Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response. Baseline data collected from i3 Health's continuing me...

Continue reading